Faculty Collaboration Database

1. D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. 2008 Oct;22(4):280-90.

2. D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E1-9.

3. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011 Oct 27;118(17):4663-5.

4. D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012 Jul 05;120(1):56-62.

5. D'Souza A, Theis JD, Vrana JA, Buadi F, Dispenzieri A, Dogan A. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol. 2012 Nov;87(11):E131-2.

6. Pardanani A, D'Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia. 2012 Nov;26(11):2439-41.

7. Jaben EA, Jacob EK, Tauscher C, D'Souza A, Hogan WJ, Stubbs JR. Clinically significant anti-A(1) in a presumed ABO-identical hematopoietic stem cell transplant recipient: a case report. Transfusion. 2013 Jan;53(1):202-5.

8. Gentile NM, D'Souza A, Fujii LL, Wu TT, Murray JA. Association between ipilimumab and celiac disease. Mayo Clin Proc. 2013 Apr;88(4):414-7.

9. D'Souza A, Theis J, Quint P, Kyle R, Gertz M, Zeldenrust S, Vrana J, Dogan A, Dispenzieri A. Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. Am J Hematol. 2013 Jul;88(7):577-80.

10. O'Reilly A, D'Souza A, Lust J, Price D. Localized tongue amyloidosis: a single institutional case series. Otolaryngol Head Neck Surg. 2013 Aug;149(2):240-4.

11. Keyzner A, D'Souza A, Lacy M, Gertz M, Hayman S, Buadi F, Kumar S, Dingli D, Engebretson A, Tong C, Dispenzieri A. Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. Biol Blood Marrow Transplant. 2013 Sep;19(9):1395-8.

12. D'Souza A, Theis JD, Vrana JA, Dogan A. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid. 2014 Jun;21(2):71-5. PMCID: PMC4021035

13. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31.

14. Dhakal B, Harrington AM, Stadler ME, D'Souza A. Localized lymph node light chain amyloidosis. Case Rep Hematol. 2015;2015:816565. PMCID: PMC4398934

15. D'Souza A, Pasquini M, Spellecy R. Is 'informed consent' an 'understood consent' in hematopoietic cell transplantation? Bone Marrow Transplant. 2015 Jan;50(1):10-4. PMCID: PMC4320584

16. Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN. Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. Bone Marrow Transplant. 2015 Mar;50(3):449-51.

17. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 2015 Apr;50(4):610-2.

18. Karam C, Klein CJ, Dispenzieri A, Dyck PJ, Mandrekar J, D'Souza A, Mauermann ML. Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome. Neurology. 2015 May 12;84(19):1981-7. PMCID: PMC4433461

19. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015 Sep;21(9):1605-11. PMCID: PMC4558181

20. Abidi MZ, D'Souza A, Kuppalli K, Ledeboer N, Hari P. CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. Diagn Microbiol Infect Dis. 2015 Sep;83(1):46-8.

21. Laine J, D'Souza A, Siddiqui S, Sayko O, Brazauskas R, Eickmeyer SM. Rehabilitation referrals and outcomes in the early period after hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Oct;50(10):1352-7. PMCID: PMC4598272

22. Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A. Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am J Hematol. 2015 Nov;90(11):E212-3. PMCID: PMC4618044

23. D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10;33(32):3741-9. PMCID: PMC4737858

24. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. PMCID: PMC4639453

25. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec;50(12):1513-8. PMCID: PMC4548821

26. Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ. DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. Case Rep Med. 2016;2016:8503275. PMCID: PMC4749780

27. Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016 Feb;51(2):297-9. PMCID: PMC4956087

28. Anthias C, Shaw BE, Kiefer DM, Liesveld JL, Yared J, Kamble RT, D'Souza A, Hematti P, Seftel MD, Norkin M, DeFilipp Z, Kasow KA, Abidi MH, Savani BN, Shah NN, Anderlini P, Diaz MA, Malone AK, Halter JP, Lazarus HM, Logan BR, Switzer GE, Pulsipher MA, Confer DL, O'Donnell PV. Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biol Blood Marrow Transplant. 2016 Mar;22(3):520-7. PMCID: PMC4760616

29. D'Souza A, Huang J, Hari P. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Apr;22(4):768-770. PMCID: PMC4801777

30. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86.

31. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 Jul;174(2):235-48. PMCID: PMC4940282

32. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 Sep 10;34(26):3141-9. PMCID: PMC5012706

33. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 Oct;22(10):1773-1780.

34. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-1899. PMCID: PMC5090978

35. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplant. 2016 Dec;51(12):1602-1604.

36. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 Jan;23(1):60-66. PMCID: PMC5182098

37. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. PMCID: PMC5346183

38. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172.

39. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):305-311.e2.

40. El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM, Majhail N, Buchbinder D, Schears RM, Wirk BM, Wood WA, Ahmed I, Aljurf M, Szer J, Beattie SM, Battiwalla M, Dandoy C, Diaz MA, D'Souza A, Freytes CO, Gajewski J, Gergis U, Hashmi SK, Jakubowski A, Kamble RT, Kindwall-Keller T, Lazarus HM, Malone AK, Marks DI, Meehan K, Savani BN, Olsson RF, Rizzieri D, Steinberg A, Speckhart D, Szwajcer D, Schoemans H, Seo S, Ustun C, Atsuta Y, Dalal J, Sales-Bonfim C, Khera N, Hahn T, Saber W. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017 May 15;123(10):1828-1838. PMCID: PMC5419891

41. Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Biol Blood Marrow Transplant. 2017 Jul;23(7):1193-1202.

42. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302.

43. Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer. 2017 Aug 15;123(16):3141-3149. PMCID: PMC5544566

44. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 Aug 31;130(9):1156-1164. PMCID: PMC5580273

45. D'Souza A, Lee S, Zhu X, Pasquini M. Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421. PMCID: PMC5565685

46. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia. 2017 Sep;31(9):1998-2000. PMCID: PMC5587375

47. D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2017 Sep;178(5):816-819. PMCID: PMC5154782

48. Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE. A phase 1 trial of ⁹⁰Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant. 2017 Oct;52(10):1372-1377.

49. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov;23(11):1955-1960.

50. D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017 Dec;8:33-38. PMCID: PMC5898504

51. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017 Dec;52(12):1616-1622. PMCID: PMC5859934

52. Badar T, D'Souza A, Hari P. Recent advances in understanding and treating immunoglobulin light chain amyloidosis. F1000Res. 2018;7. PMCID: PMC6117860

53. Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018 Feb 15;124(4):816-825. PMCID: PMC5871233

54. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01;4(3):343-350. PMCID: PMC5885822

55. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. PMCID: PMC5826888

56. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018 Apr;32(4):986-995. PMCID: PMC5871538

57. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. PMCID: PMC5865423

58. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr 24;2(8):933-940. PMCID: PMC5916010

59. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018 May 24;18(1):593. PMCID: PMC5968588

60. Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):105-111.

61. Wright NL, Flynn KE, Brazauskas R, Hari P, D'Souza A. Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. Amyloid. 2018 Jun;25(2):129-134.

62. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Aug;24(8):1610-1614.

63. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670.

64. D'Souza A, Millard H, Knight J, Brazauskas R, Lee SJ, Flynn KE, Rizzo JD, Shaw BE. Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018 Aug;53(8):1079-1082. PMCID: PMC6098949

65. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213.

66. Quock TP, Chang E, Munday JS, D'Souza A, Gokhale S, Yan T. Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis. J Comp Eff Res. 2018 Nov;7(11):1053-1062.

67. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018 Nov;74:130-136. PMCID: PMC6219911

68. Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. PMCID: PMC6293469

69. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833.

70. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (&lt;24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. PMCID: PMC6453717

71. Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 Jan;25(1):e33-e38.

72. Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant. 2019 Feb;25(2):335-342. PMCID: PMC6339830

73. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 Jun;25(6):1099-1106. PMCID: PMC6559839

74. Patel G, Hari P, Szabo A, Rein L, Kreuziger LB, Chhabra S, Dhakal B, D'Souza A. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):10-14.

75. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497.

76. Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Oncologist. 2019 Sep;24(9):1253-1258. PMCID: PMC6738285

77. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 Jul 03;2(7):e196476.

78. Quock TP, Yan T, Tieu R, D'Souza A, Broder MS. Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clinicoecon Outcomes Res. 2019;11:431-439. PMCID: PMC6643051

79. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. PMCID: PMC6663939

80. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec;26(4):210-215.

81. D'Souza A, Hari P, Pasquini M, Jacobsen K, Flynn KE. Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. Amyloid. 2019;26(sup1):87-88. PMCID: PMC7108667

82. Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. J Clin Apher. 2019 Dec;34(6):686-691. PMCID: PMC6957224

83. Warsame R, D'Souza A. Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology. Mayo Clin Proc. 2019 Nov;94(11):2291-2301. PMCID: PMC6832764

84. Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, Kumar AJ, Yoshimi A, Wirk B, Shaw B, Freytes C, LeMaistre C, Bredeson C, Dandoy C, Almaguer D, Marks DI, Szwajcer D, Hale G, Schouten H, Hashem H, Schoemans H, Murthy HS, Lazarus HM, Cerny J, Tay J, Yared JA, Adekola K, Schultz KR, Lehmann L, Burns L, Aljurf M, Diaz MA, Majhail N, Farhadfar N, Kamble R, Olsson R, Schears R, Seo S, Beattie S, Chhabra S, Savani BN, Badawy S, Ganguly S, Ciurea S, Marino S, Gergis U, Kuwatsuka Y, Inamoto Y, Khera N, Hashmi S, Wood W, Saber W. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2020 Mar;26(3):553-561. PMCID: PMC7367505

85. Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E. In Reply. Oncologist. 2020 Apr;25(4):e744-e745. PMCID: PMC7160403

86. Dunavin N, Mau LW, Meyer CL, Divine C, Abdallah AO, Leppke S, D'Souza A, Denzen E, Saber W, Burns LJ, Ganguly S. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. Biol Blood Marrow Transplant. 2020 Apr;26(4):805-813.

87. Bhasin B, Szabo A, Wu R, Saad ER, Hari P, Dhakal B, Chhabra S, D'Souza A. Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e468-e473. PMCID: PMC7450520

88. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 Dec;34(12):3338-3347. PMCID: PMC7572530

89. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. PMCID: PMC7194895

90. Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer. 2020 Jun 15;126(12):2791-2801.

91. Cusatis RN, Tecca HR, D'Souza A, Shaw BE, Flynn KE. Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. Cancer. 2020 Jun 01;126(11):2679-2686. PMCID: PMC7220834

92. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 Feb 11;4(3):467-476. PMCID: PMC7013267

93. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 May;26(5):893-901.

94. D'Souza A, Magnus BE, Myers J, Dispenzieri A, Flynn KE. The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid. 2020 Jun;27(2):111-118. PMCID: PMC7275879

95. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. PMCID: PMC7404814

96. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2020 Jul;26(7):e161-e166. PMCID: PMC7206419

97. Dhakal B, D'Souza A, Chhabra S, Hari P. Multiple myeloma and COVID-19. Leukemia. 2020 Jul;34(7):1961-1963.

98. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020 Aug;35(4):307-315.

99. D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN. Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. EClinicalMedicine. 2020 Jun;23:100361. PMCID: PMC7280748

100. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859

101. Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P. Salvage second transplantation in relapsed multiple myeloma. Leukemia. 2021 Apr;35(4):1214-1217. PMCID: PMC8020391

102. Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A. Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Jan;56(1):225-231. PMCID: PMC7855279

103. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017.

104. Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Leuk Lymphoma. 2020 Dec;61(14):3484-3492. PMCID: PMC7786301

105. Mehta A, Fillmore N, Dahiya S, D'Souza A, Sweetenham J, Kansagra A. Reporting of race and ethnicity at an international haematology conference. Br J Haematol. 2020 Dec;191(5):e107-e109.

106. Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biol Blood Marrow Transplant. 2020 Dec;26(12):2229-2236.

107. Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2021 Jan 01;127(1):82-92. PMCID: PMC7736245

108. Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec 01;126(23):5077-5087. PMCID: PMC8063213

109. Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 Nov;191(3):442-452. PMCID: PMC7990054

110. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70. PMCID: PMC7543702

111. Tay J, Beattie S, Bredeson C, Brazauskas R, He N, Ahmed IA, Aljurf M, Askar M, Atsuta Y, Badawy S, Barata A, Beitinjaneh AM, Bhatt NS, Buchbinder D, Cerny J, Ciurea S, D'Souza A, Dalal J, Farhadfar N, Freytes CO, Ganguly S, Gergis U, Gerull S, Lazarus HM, Hahn T, Hong S, Inamoto Y, Khera N, Kindwall-Keller T, Kamble RT, Knight JM, Koleva YN, Kumar A, Kwok J, Murthy HS, Olsson RF, Angel Diaz-Perez M, Rizzieri D, Seo S, Chhabra S, Schoemans H, Schouten HC, Steinberg A, Sullivan KM, Szer J, Szwajcer D, Ulrickson ML, Verdonck LF, Wirk B, Wood WA, Yared JA, Saber W. Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes. Curr Oncol. 2020 Dec;27(6):e596-e606. PMCID: PMC7755447

112. Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Transl Psychiatry. 2021 Jan 18;11(1):58. PMCID: PMC7812704

113. D'Souza A, Brazauskas R, Dispenzieri A, Panepinto J, Flynn KE. Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. Blood Cancer J. 2021 Feb 01;11(2):29. PMCID: PMC7873213

114. D'Souza A, Pezzin L, Laud P, Singh A. Racial disparities in patients diagnosed with light chain (AL) amyloidosis. Blood Cancer J. 2021 Apr 10;11(4):72. PMCID: PMC8036230

115. Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A. Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2021 Jul;27(7):617.e1-617.e7. PMCID: PMC8254775

116. Bhasin B, Ber Ce P, Szabo A, Chhabra S, D'Souza A. Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation. Am J Med Sci. 2021 Jul;362(1):72-77.

117. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun;35(6):1828. PMCID: PMC8188513

118. Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. Transplant Cell Ther. 2021 Mar;27(3):264.e1-264.e7. PMCID: PMC8010222

119. Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 May;27(5):410-422. PMCID: PMC8168834

120. Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A. Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. Leuk Res. 2021 Oct;109:106648.

121. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jul;35(7):2141.

122. Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 Dec;35(12):3526-3533. PMCID: PMC8632673

123. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e775-e781.

124. Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer. 2021 Nov 15;127(22):4233-4239. PMCID: PMC8699178

125. D'Souza A, Myers J, Cusatis R, Dispenzieri A, Finkel M, Panepinto J, Flynn KE. Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. Qual Life Res. 2022 Apr;31(4):1083-1092. PMCID: PMC8993595

126. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 Jan;57(1):31-37. PMCID: PMC8764606

127. Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022 Apr 26;6(8):2466-2470. PMCID: PMC9043928

128. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 Feb;28(2):83.e1-83.e9. PMCID: PMC8900987

129. Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2022 Sep 01;40(25):2901-2912.

130. Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant. 2022 Feb;57(2):295-298. PMCID: PMC8825695

131. Lin M, Pezzin LE, Mohamedi A, Kansagra A, D'Souza A. Prevalence of Race/Ethnicity Reporting in Light Chain (AL) Amyloidosis Clinical Research in the USA. J Racial Ethn Health Disparities. 2023 Apr;10(2):644-650. PMCID: PMC9339584

132. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022 Apr 11;40(4):340-342. PMCID: PMC8864440

133. Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM. Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. Yale J Biol Med. 2022 Mar;95(1):45-56. PMCID: PMC8961707

134. D'Souza A, Costa LJ. MGIP, MGUS, and the PROMISE of meaning in small things. Lancet Haematol. 2022 May;9(5):e315-e317.

135. Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P. Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J. 2022 Feb 24;12(2):34. PMCID: PMC8873507

136. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022 Jul;28(7):409.e1-409.e10. PMCID: PMC9840526

137. Schwein PA, Ge Y, Yang B, D'Souza A, Mody A, Shen D, Woo CM. Writing and Erasing O-GlcNAc on Casein Kinase 2 Alpha Alters the Phosphoproteome. ACS Chem Biol. 2022 May 20;17(5):1111-1121. PMCID: PMC9647470

138. S R, V P, D'Souza AO, Vinod R. Comparison of Phenotypic and Genotypic Characterization Methods for the Detection of Methicillin-Resistant Staphylococcus Aureus. Cureus. 2022 Mar;14(3):e23396. PMCID: PMC9033515

139. Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr., Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 Jul 12;6(13):3991-3995. PMCID: PMC9278304

140. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 Jul;97(7):E276-E280. PMCID: PMC10476149

141. Malik MA, Sweeney NW, Jafri M, Derkach A, Chmielewski C, Adintori PA, Mailankody S, Korde N, Tan CR, Hassoun H, Hultcrantz M, Hillengass J, McCann SE, Iyengar N, Usmani S, Giralt SA, Landgren O, van den Brink MRM, Ahlstrom JM, Lesokhin AM, D'Souza A, Chimonas S, Shah UA. Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer J. 2022 Apr 20;12(4):70. PMCID: PMC9021216

142. D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2023 Jan;98(1):140-147. PMCID: PMC9659666

143. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) Transplantation and Cellular Therapy. 2021.

144. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182] (Transplantation and Cellular Therapy (2020) 26/8(e177-e182) (S1083879120302251), (10.1016/j.bbmt.2020.04.013)) Transplantation and Cellular Therapy. 2021.

145. Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, Shaw BE, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues The Lancet Haematology. August 2022;9(8):e605-e614.

146. Krishnamurti L, Arnold SD, Haight A, Abraham A, Guilcher GM, John T, Bakshi N, Shenoy S, Syrjala K, Martin PL, Chaudhury S, Eames G, Olowoselu OF, Hsieh M, De La Fuente J, Kasow KA, Stenger E, Mertens A, El-Rassi F, Lane P, Shaw BE, Meacham L, Archer D. Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study. JMIR Res Protoc. 2022 Jul 06;11(7):e36780. PMCID: PMC9301564

147. Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, Chhabra S, Medvedova E, Godby KN, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS, Costa LJ. Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. Am J Hematol. 2022 Sep;97(9):1170-1177.

148. Farhadfar N, Ahn KW, Bo-Subait S, Logan B, Stefanski HE, Hsu JW, Panch S, Confer D, Liu H, Badawy SM, Beitinjaneh A, Diaz MA, Hildebrandt GC, Kelkar AH, Lazarus HM, Murthy HS, Preussler JM, Schears RM, Sharma A, van der Poel M, Bruce JG, Pulsipher MA, Shaw BE, Wingard JR, Switzer GE. The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplant Cell Ther. 2022 Sep;28(9):603.e1-603.e7. PMCID: PMC9427696

149. Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, Shaw BE, Satwani P. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 May 12;4(9):2084-2094. PMCID: PMC7218429

150. Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. 2022 May 25;12(5):82. PMCID: PMC9132975

151. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):863-868.

152. D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 01;40(31):3576-3586. PMCID: PMC9622641

153. Gallan AJ, Bhasin-Chhabra B, Kilari D, Johnson S, D'Souza A. Bystander LECT2 amyloidosis in tumor nephrectomy. CEN Case Rep. 2023 Feb;12(1):104-109. PMCID: PMC9892383

154. Hodge A, Sheean P, O'Connor P, Tyler K, Kerschner A, Williams A, Jensik K, Visotcky A, D'Souza A, Hari P, Dhakal B, Chhabra S, Flynn KE, Hagen P, Stolley M. Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. Support Care Cancer. 2022 Dec;30(12):9771-9779.

155. Dispenzieri A, Zonder J, Hoffman J, Wong SW, Liedtke M, Abonour R, D'Souza A, Lee C, Cote S, Potluri R, Ammann E, Tran N, Lam A, Nair S. Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases. Amyloid. 2023 Jun;30(2):161-168.

156. D'Souza A, Broder MS, Bognar K, Chang E, Tarbox MH, Quock TP. Diagnostic amyloid light chain amyloidosis hospitalizations associated with high acuity and cost: analysis of the Premier Healthcare Database. J Comp Eff Res. 2022 Dec;11(17):1225-1230.

157. Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE. Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. Am J Hematol. 2023 Feb;98(2):229-250. PMCID: PMC9839494

158. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct;28(10):717.

159. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. Transplant Cell Ther. 2022 Oct;28(10):715-716.

160. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 Dec;97(12):E451-E453.

161. Cusatis R, Litovich C, Spellecy R, Liang A, D'Souza A. Navigating the perils and pitfalls throughout the consent process in hematopoietic cell transplantation. Blood Rev. 2023 May;59:101037. PMCID: PMC10548336

162. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 Apr;58(4):443-445.

163. Quock TP, D'Souza A, Broder MS, Bognar K, Chang E, Tarbox MH. In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database. J Comp Eff Res. 2023 Feb;12(2):e220185. PMCID: PMC10288963

164. D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S. DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma. Bone Marrow Transplant. 2023 Mar;58(3):334-336.

165. Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M. Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. JAMA Netw Open. 2022 Oct 03;5(10):e2238961. PMCID: PMC9617177

166. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr., Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 Jun 27;7(12):2746-2757. PMCID: PMC10275699

167. D'Souza A, Szabo A, Akinola I, Finkel M, Flynn KE. A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis. Qual Life Res. 2023 Jun;32(6):1807-1817. PMCID: PMC10350248

168. D'Souza A, Kumar S. Reply to E.R.S. Cliff et al. J Clin Oncol. 2023 Apr 01;41(10):1951-1952.

169. Cusatis R, Ibrahim A, Knight JM, D'Souza A, Shaw BE. Prevalence of Sleep Aid Medication Use in Patients Receiving a Hematopoietic Cell Transplant on an Inpatient Unit. Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):366-369.

170. Bacos JT, Doren E, D'Souza A, Jorns J, Kong A. Surgical Management of Breast Amyloidosis. Clin Breast Cancer. 2023 Aug;23(6):e359-e367.

171. Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, D'Souza A, Pappas PG, Berdeja JG, Callander N, Costa LJ. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023 Dec;203(5):736-746. PMCID: PMC10700672

172. Rizio AA, White MK, D'Souza A, Hsu K, Schmitt P, Quock TP, Signorovitch J, Lousada I, Sanchorawala V. Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group. Patient Relat Outcome Meas. 2023;14:153-169. PMCID: PMC10202704

173. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D'Souza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian H. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023 Dec 01;108(12):3384-3391. PMCID: PMC10690919

174. D'Souza A, Szabo A, Akinola I, Finkel M, Flynn KE. Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis. Eur J Haematol. 2023 Oct;111(4):536-543. PMCID: PMC10530507

175. Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant. 2023 Aug;58(8):953-955. PMCID: PMC10555486

176. El Jurdi N, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, Shapiro RM, Horowitz MM, Hamilton BK. Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101. Transplant Cell Ther. 2023 Jul;29(7):467.e1-467.e5. PMCID: PMC10330136

177. Palmen B, Hari P, D'Souza A, Abid MB. Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen. Haematologica. 2023 Nov 01;108(11):3186-3190. PMCID: PMC10620554

178. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 Jul 15;129(14):2179-2191. PMCID: PMC10516285

179. Shaw BE, Flynn KE, He N, Cusatis R, D'Souza A, Hamilton BK, Horowitz MM, Mattila D, Phelan R, Lee SJ, Brazauskas R. Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients. Cancer. 2024 May 15;130(10):1826-1835. PMCID: PMC11058023

180. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Mar;59(3):373-379.

181. Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 Mar;30(3):285-297.

182. D'Souza A. Amyloid consults do not have to be vexing. Hematology Am Soc Hematol Educ Program. 2023 Dec 08;2023(1):407-412. PMCID: PMC10727086

183. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar;204(3):887-891.

184. Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023 Nov 27;13(1):172. PMCID: PMC10682473

185. Bal S, Estrada-Merly N, Costa LJ, Qazilbash MH, Kumar S, D'Souza A. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies. Blood Cancer J. 2023 Nov 15;13(1):170. PMCID: PMC10651880

186. Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J. Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance. Leukemia. 2024 Feb;38(2):383-385. PMCID: PMC11326531

187. Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium. Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. Bone Marrow Transplant. 2024 Jan;59(1):121-124.

188. Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023 Nov;10(11):e890-e901. PMCID: PMC10836587

189. Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD Jr, D'Souza A. Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone Marrow Transplant. 2023 Dec;58(12):1400-1402. PMCID: PMC11646697

190. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 Mar 01;109(3):906-914. PMCID: PMC10905074

191. D'Souza A, Singh A, Szabo A, Lian Q, Pezzin L, Sparapani R. Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis. Res Sq. 2024 Jan 03. PMCID: PMC10802702

192. Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May;59(5):647-652.

193. D'Souza A, Szabo A, Akinola I, Finkel M, Flynn KE. Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis. Eur J Haematol. 2024 Jun;112(6):900-909. PMCID: PMC11271248

194. Brazauskas R, Flynn K, Krishnan A, Landau H, Giralt S, Pasquini MC, Stadtmauer EA, D'Souza A. Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial. Br J Haematol. 2024 Apr;204(4):1429-1438. PMCID: PMC11006567

195. Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 2024 Mar 06;14(1):38. PMCID: PMC10915134

196. Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024 Mar 05;14(1):35. PMCID: PMC10914756

197. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan M. Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood Cancer J. 2024 Mar 05;14(1):36. PMCID: PMC10914796

198. Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS. Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2024 Dec;205(6):2370-2375.

199. Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8.

200. Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, D'Souza A. Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center. Transplant Cell Ther. 2024 Dec;30(12):1189.e1-1189.e10.

201. Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A, Kumar S, D'Souza A, Patwari A, Cowan A, Chen G, Milani P, Palladini G, Sanchorawala V, Bodanapu G, Schönland SO, Lentzsch S, Muchtar E. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy. Blood. 2024 Dec 19;144(25):2613-2624.

202. Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. Br J Haematol. 2024 Nov;205(5):1830-1834.

203. Hagen P, D'Souza A. Autologous stem cell transplantation in AL amyloidosis: Muddy waters. Blood Rev. 2024 Nov;68:101228. PMCID: PMC11568934

204. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood Cancer J. 2024 Aug 12;14(1):137. PMCID: PMC11319778

205. Kim M, Arabi J, McCoy C, D'Souza A, Chhabra S, Abid MB, Thapa B, Dhakal B. Safety of Dapsone for Pneumocystis Jiroveci Pneumonia Prophylaxis in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):804-807.

206. Estrada-Merly N, Maurer MS, D'Souza A. Glaucoma is not seen at a higher prevalence in age-related transthyretin amyloidosis after race stratification. Amyloid. 2024 Dec;31(4):339-341. PMCID: PMC11598661

207. Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 Aug 27;8(16):4320-4329. PMCID: PMC11372811

208. Singh A, Szabo A, Lian Q, Pezzin L, Sparapani R, D'Souza A. Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis. Blood Cancer J. 2024 May 26;14(1):61. PMCID: PMC11127981

209. Akinola I, Flynn KE, Szabo A, Finkel M, D'Souza A. Patient-reported satisfaction with telemedicine in light chain (AL) amyloidosis care. Amyloid. 2024 Sep;31(3):235-237. PMCID: PMC11330728

1. D'Souza A, Pasquini M, Wang Z, Rizzo D. Current Trends and Indications for Hematopoietic Cell Transplantation. In: Lazarus HM,Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, Abutalib S. (editors) Current Concepts and Controversies in Hematopoietic Cell Transplantation, Cambridge University Press, Cambridge, UK, 2014.

2. Hussain AS and D’Souza A. Light Chain Amyloidosis. In: Zimmerman TM, Kumar SK (editors) Biology and Management of Unusual Plasma Cell Dyscrasias, Springer, 2016.

3. Hussain AS and D’Souza A. Light chain amyloidosis. In: Clinical Manual of Blood and Bone Marrow Transplantation, Wiley, 2017.

4. D'Souza A, Pardanani A, Tefferi A. Lymphoma-associated versus lymphocytic-variant hypereosinophilia. Leuk Lymphoma. 2012 Nov;53(11):2103-4.

5. D'Souza A, Ansell S, Reeder C, Gertz MA. Waldenström macroglobulinaemia: the key questions. Br J Haematol. 2013 Aug;162(3):295-303.

6. Ramakrishnan V, D'Souza A. Signaling Pathways and Emerging Therapies in Multiple Myeloma. Curr Hematol Malig Rep. 2016 Apr;11(2):156-64.

7. D'Souza A, Spellecy R, Derse A. Engender trust and edify. Bone Marrow Transplant. 2018 Jan;53(1):104.

8. D'Souza A, Gertz MA. Waldenström's Macroglobulinemia Cancer Consult: Expertise for Clinical Practice. June 20, 2014:371-375.

9. Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S. Autonomic nervous system control of multiple myeloma. Blood Rev. 2021 Mar;46:100741. PMCID: PMC7876165

10. Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021;12:667054. PMCID: PMC8206561

11. D'Souza A. and Hari, PN. Transplantation for light chain amyloidosis. In: Hematopoietic Cell Transplantation for Malignant Conditions, Elsevier, 2018.

1. Shaw BE, D'Souza A, Lee SJ. Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. J Clin Oncol. 2019 Jul 01;37(19):1598-1600. PMCID: PMC6879316

2. D'Souza A, Lonial S. What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. J Clin Oncol. 2021 Aug 01;39(22):2423-2425.

1. Clupper, DC, D'Souza A, Jaroch DB, Modulation of Ciprofloxacin Release from Sol-Gel derived Silica Matrices, Poster Presentation at the 32nd Annual Meeting of the Society for Biomaterials, Chicago, IL, 2007

2. D'Souza A, Muckey B, Azrak F, Hydralazine- Induced Pulmonary- Renal Syndrome, Oral Presentation at American College of Physicians(ACP) Associates Meeting, Michigan Chapter, Sterling Heights, MI, 05/2008 (First place, Oral presentation-Case report)

3. D'Souza A, Muckey B, Azrak F, Hydralazine- Induced Pulmonary- Renal Syndrome, Oral Presentation at Michigan American College of Physicians(ACP) Regional conference, Detroit, MI, 09/2008 (Third place, Oral presentation-Case report).

4. D'Souza A, Mukherjee S, Barnes M, Eosinophilia-An Unusual Manifestation of a Common Disease or a Mere Confounding Association? Poster Presentation at American College of Physicians(ACP) National Meeting, Washington D.C., 05/2008

5. D'Souza A, Moukabary T, Shoichet S, Fatal Sickling Crisis Triggered by Previously Undiagnosed Lupus. Poster Presentation at American College of Physicians(ACP) National Meeting, Washington D.C., 05/2008

6. D'Souza A, Agrawal V, Barnes MA, A Dermatological Surprise Associated with Subclinical Chronic Lymphocytic Leukemia, Poster Presentation at American College of Physicians(ACP) Michigan Chapter, Traverse City, MI, 09/2008

7. D'Souza A, All that wheezes is not Asthma, Poster Presentation at American College of Physicians (ACP) Michigan Chapter, Sterling Heights, MI, 09/2009

8. Pieper M, D'Souza A, Wolanskyj A, An Atypical Normocytic Anemia- Mind the Medication List, Poster Presentation at American College of Physicians(ACP) Minnesota Chapter, Minneapolis, MN, 11/2010

9. D'Souza A, Doherty L, Ducaine W, Zakalik D. Impact of BRCA1/BRCA2 gene mutation testing on surgical decision-making in newly diagnosed breast cancer patients. Cancer Res. 2010;70(24 Suppl):P2-10-03.

10. D'Souza A, Hayman S, Buadi F, Gertz M, Lacy M, Mauermann M, Greipp P, Zeldenrust S, Kumar S, Kyle R, Lust J, Detweiler K, Dingli D, Russell S, Witzig T, Rajkumar SV, Dispenzieri A. Baseline plasma VEGF levels in POEMS and related disorders. Haematologica 2011;96S:S154

11. D'Souza A, Hayman S, Buadi F, Gertz M, Lacy M, Mauerman M, Greipp P, Zeldenrust S, Kumar S, Kyle R, Lust J, Detweiler K, Dingli D, Russell S, Witzig T, Rajkumar SV, Dispenzieri A. Utility of plasma VEGF levels in the follow-up of patients with POEMS. Haematologica 2011;96S:S157.

12. D'Souza A, Outcomes after autologous stem cell transplantation for POEMS syndrome (osteosclerotic myeloma): A single center experience, Oral Presentation at the First Annual Mentoring Program for Stem Cell Transplantation Fellows, Atlanta, GA, 01/2012

13. D'Souza A, Theis J, Quint P, Vrana J, Gertz M, Kyle R, Zelderust S, Dogan A, Dispenzieri A. Amyloidosis of lymph nodes: a proteomic analysis using tandem mass spectrometry. Amyloid 2013.

14. Jaben E, Tauscher C, D'Souza A, Hogan W, Stubbs J, Eapen J Clinically significant anti-A1 (ABO) in a presumed ABO-identical hematopoietic stem cell (HSC) transplant recipient. Transfusion 2011;51s:220A

15. D'Souza A, Armasu S, De Andrade M, Heit J Replication of Candidate Gene Single Nucleotide Polymorphisms (SNPs) Previously Reported As Associated with Venous Thromboembolism. Blood 2011;118:123.

16. D'Souza A, Buadi F, Lacy M, Gertz M, Hayman S, Kumar S, Dingli D, Zeldenrust S, Dispenzieri A Relapse of POEMS Syndrome following autologous stem cell transplantation: a single center experience. Blood 2011;118:3101.

17. D'Souza A, Buadi F, Lacy M, Gertz M, Hayman S, Kumar S, Dingli D, Zeldenrust S, Kyle R, Dispenzieri A, Outcomes after autologous stem cell transplantation for POEMS syndrome (osteosclerotic myeloma): A single center experience, Poster Presentation at the 22nd Annual Mayo Clinic Hematology/Oncology Reviews, 2012. Received a Fellow Travel Award.

18. O'Reilly A, D'Souza A, Price D Localized amyloidosis of the tongue: A review of the Mayo Clinic experience. Otolaryngol Head Neck Surg 2012;147:P165.

19. Mereuta O, D'Souza A, Vrana J, Theis J, Quint P, Dispenzieri A, Grogg K, Dogan A. Localized Amyloidosis of the Urinary Bladder: New Pathological Features Revealed by Mass Spectrometry-Based Proteomics. Modern Pathology. Mod Pathol. 2013;26:234A

20. Mereuta O, D'Souza A, Vrana J, Theis J, Quint P, Dispenzieri A, Grogg K, Dogan A Amyloidosis of the Urinary Bladder: New Pathological Features Revealed by Mass Spectrometry-Based Proteomics. Mod Pathol. 2013;26:234A. Lab Invest. 2013;93:234A.

21. D'Souza A, Theis J, Vrana J, Dogan A. Drug-induced amyloidosis: a proteomic insight into 52 cases. Blood 2013;122:1871.

22. Karam C, Klein C, Dispenzieri A, Mandrekar J, Dyck J, D'Souza A, Mauermann M. Neuropathy Improvement following Peripheral Blood Stem Cell Transplantation for POEMS Syndrome. Neurology 2014 82(10):Supplement I6-2.002

23. D'Souza A, Wirk B, Zhang, MJ, Huang J, Krishnan A, Mark T, Gasparetto C, Hari PN. Improved Outcomes of Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study. Blood 2014;124:193

24. Costa LJ, Uy G, Hari PN, Zhang MJ, Huang J, Krishnan A, Mark TM, D'Souza A. Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. Blood 2014;124:2447.

25. Dhakal B, Brazauskas R, Arce-Lara C, Hari PN, Pasquini MC, D'Souza A. Monocyte Recovery at Day 100 is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl 2015; 21(2):S163-S164.

26. Dhakal B, Martens M, Kapke J, D'Souza A, Pasquini M, Saber W, Hamadani M, Drobyski W, Horowitz M, Zhang M-J, Hari P. Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Impact of Disease Risk and Conditioning Regimen. Biol Blood Marrow Transpl 2015; 21(2):S278-S279.

27. Hari P, Cornell RF, Zhang MJ, Huang J, Kassim A, Costa L, Innis-Shelton RD, Mark T, Nieto YL, Gasparetto C, Krishnan A, D'Souza A. Induction regimens for autologous transplant eligible myeloma patients- Doublets or Triplets and Which Triplet? Clinical Lymphoma, Myeloma and Leukemia, 2015; 15: e51.

28. D'Souza A, Huang J, Hari P. Validation of the 2012 hematologic response criteria in light chain amyloidosis using the Center for International Blood and Marrow Transplant (CIBMTR) database. Clinical Lymphoma Myeloma and Leukemia, 2015; 15: e182-e183

29. Hari P, Cornell RF, Zhang MJ, Huang J, Kassim A, Costa L, Innis-Shelton RD, Mark T, Nieto YL, Gasparetto C, Krishnan A, D'Souza A. Induction regimens for autologous transplant eligible myeloma patients- Doublets or Triplets and Which Triplet? Poster with Discussion at the 15th International Myeloma Workshop, Clinical Lymphoma, Myeloma and Leukemia 2015; 15: e51.

30. D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin JH, Howard A, Horowitz M, Goodman S, Laport G, Qazilbash MH, Mendizabal MS, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P, Heavy Light Chain Ratio Normalization Allows Identification of Electrophoretic Non-Complete Response Patients with Improved Outcomes: A Long Term Follow Up Update for BMT CTN 0102 Correlative Study. Poster Presentation at the 20th Annual European Hematology Association Meeting, Haematologica 2015;S1:P664.

31. Dhakal B, Ramalingam S, Shuff J, Epperla N, Rein L, Banerjee A, Siker M, Hosking PR, Hari P, D'Souza A, Atallah E, Erickson B, Fenske TS, Hamadani M. Local Control of Ocular Adnexal Lymphoproliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Poster Presentation at 57th Annual Meeting of the American Society of Hematology, Blood 2015;126:2711

32. Cornell RF, Costa LJ, Kassim AA, Inns-Shelton R, Krishnan A, Mark T, Nieto Y, Gasparetto CJ, D'Souza A, Hari P, Zhang MJ, Huang J. Post-Transplant Therapy is More Important Than Induction Regimen Chocie in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). Oral Presentation at 57th Annual Meeting of the American Society of Hematology, Blood 2015;126:396

33. Sharma M, Hari P, Le-Rademacher J, Krishnan A, Nieto Y, Gasparetto C, Huang J, Scott EC, D'Souza A. Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post-Transplant Responses Do Not Translate to Longer Survival. Poster Presentation at 57th Annual Meeting of the American Society of Hematology, Blood 2015; 126: 1979

34. Hamadani M, Pasquini M, Visotcky A, Ahn KW, Horowitz MM, Boyd J, Rizzo JD, Saber W, Drobyski W, Arce-Lara C, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Hari PN, Kanate AS. Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT). Oral presentation at Annual BMT Tandem Meetings 2016, Biol Blood Marrow Transpl 2016;22(3):S47-S48.

35. Muffly L, Pasquini M, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Artz A, Bajel A, Ballen K, Battiwalla M, Beitinjaneh A, Cahn J-Y, Carabasi M, Chen Y-B, Saurabh C, Ciurea S, Copelan E, D'Souza A, Edwards J, Freytes C, Fung H, Gale RP, Giralt S, Hashmi S, Hematti P, Hildebrandt G, Ho V, Jakubowski A, Lazarun H, Mccarthy P, Olin R, Olsson R, Rezvani A, Rizzieri D, Seftel D, Seo D, Sorror M, Szer J, Wood W Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes. Poster presentation at the Annual BMT Tandem Meetings 2016, Biol Blood and Marrow Transpl. 2016;22(3)Supplement:S68-S69.

36. Thompson J, Drobyski W, D'Souza A, Fenske T, Hamadani M, Hari P, Pasquini M, Saber W, Rizzo D. Etanercept for Late Onset Idiopathic Pneumonia Syndrome. Poster presentation at the Annual BMT Tandem Meetings 2016, Biol Blood and Marrow Transpl 2016;22(3)Supplement:S359

37. Cornell F, Bachanova V, D'Souza A, Ahn KW, Huang J, Krishnan A, Gasparetto C, Nieto Y, Mark T, Hari P. Outcomes after Allogeneic Transplant for Lymphoplasmacytic Lymphoma/Waldenstron Macroglobulinemia: A Center for International Blood and Marrow Transplant Research. Poster presentation at the Annual BMT Tandem Meetings 2016, Biol Blood Marrow Transplant. 2016;22(3)Supplement:S219

38. D’Souza A, Pasquini M, Hari P, Jacobson K, Jacobs P, Flynn K. Patient-reported outcomes in light chain amyloidosis: choosing the optimal tool. Poster presentation at the HealthMeasures User Workshop, Chicago, IL 05/2016 and at the International Symposium on Amyloidosis 07/2016 (Awarded Travel Grant).

39. Hammons L, Brazauskas R, Hari P, Arce-Lara C, Pasquini M, D’Souza A. Abnormal molecular markers are associated with clonal plasma cell burden in light chain amyloidosis. Poster presentation at the American Society of Clinical Oncology Annual Meeting, June 2016.

40. Voshtina E, Szabo A, Hamadani M, Fenske T, D’Souza A, Saber W, Drobyski W, Hari P, Shah N. Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. Poster presentation at 58th Annual Meeting of the American Society of Hematology, Blood 2016.

41. Dhakal B, D’Souza A, Zhang MJ, Hamadani M, Hari P. Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. Poster presentation at 58th Annual Meeting of the American Society of Hematology, Blood 2016.

42. Abidi M, Stoll C, D’Souza A, Pasquini M, Saber W, Fenske T, Rizzo JD, Drobyski W, Keever-Taylor C, Hari P. Importance of Site Preparation in Reducing the Risk of Bacterial Contamination during Bone Marrow Harvest. Poster presentation at the 2017 BMT Tandem Meetings, BBMT 2017.

43. Hari P, Dhakal B, D’Souza A, Thompson R, Hamadani M, Pasquini M, Chhabra S. Pharmacokinetics of Propylene Glycol-Free Melphalan HCl in Multiple Myeloma Patients Undergoing Autologous Transplantation. Poster presentation at the 2017 European Hematologic Association Meeting. Haematologica 2017;102:621.

44. Dhakal B, Chhabra S, Hamadani M, D’Souza A, Usmani S, Jackson J, Hari P. Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized clinical trials. Poster presentation at the 2017 ASCO Annual Meeting.

45. Dhakal B, D’Souza A, Hamadani M, Arce-Lara C, Schroeder K, Gauger K, Crone K, Pasquini M, Chhabra S, Hari P. Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma: Phase I safety and dosing results. Poster presentation with discussion at the 2017 ASCO Annual Meeting. J Clin Oncol. 2017;35 (15_suppl):8012.

46. Patel G, Hari P, Szabo A, Rein L, Baumann Kreuziger L, Chhabra S, Dhakal B, D’Souza A. Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease. Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017. (Ms. Patel received a 2017 ASH Abstract Achievement Award).

47. D’Souza A, Millard H, Knight J, Brazauskas R, Flynn K, Lee SJ, Horowitz M, Rizzo D, Shaw B. Patient-Reported Sleep Quality at Baseline Correlates with 1-Year Survival after Allogeneic Hematopoietic Cell Transplantation in Adults. Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017.

48. Scott E, Hari P, Kumar S, Fraser R, Davila O, Nieto Y, Mark T, Kumar S, Gasparetto C, D’Souza A. A Comparison Between 3 Staging Systems in Multiple Myeloma Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Database. Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017.

49. Kumar S, D’Souza A, Scott E, Fraser R, Davila O, Gasparetto C, Kumar S, Mark T, Nieto Y, Hari P. Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (<24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM). Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017.

50. Chhabra S, Hari P, Visotcky, Shah N, Rizzo D, Saber W, D’Souza A, Dhakal B, Anshu A, Thompson R, Fenske T, Shaw B, Drobyski W, Pasquini M, Hamadani M. Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study. Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017.

51. Dhakal B, Narra R, Smunt T, Canadeo A, Chhabra S, D’Souza A, Gyawali B, Hari P, Niraula S. Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017.

52. Dhakal B, Qi X, Guru Murthy, GS, Narra R, Szabo A, Chhabra S, D’Souza A, Hari P. Using “Big-Data” to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT) Poster presentation at 59th Annual Meeting of the American Society of Hematology, Blood 2017.

53. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski W, Fenske T, Hamadani M, Pasquini M, Saber N, Shah NN, Shaw B, D’Souza A. Use of Propylene Glycol-Free Melphalan Conditioning in Light Chain Amyloidosis Patients Undergoing Autologous Hematopoietic Cell Transplantation is Associated with Significantly Lower Hospitalization Days. Poster presentation at the 2018 BMT Tandem Meetings, BBMT 2018.

54. Knight JM, Rizzo JD, Hari P, Kerswill S, D’Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Cole SW. Propranolol inhibits stress-related gene expression profiles associated with adverse clinical outcomes in autologous hematopoietic cell transplantation recipients. Poster presentation at the 2018 BMT Tandem Meetings, BBMT 2018.

55. Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Hillard CJ, Rizzo JD, D’Souza A, Coe CL, Drobyski WR. Pre-transplant tocilizumab is associated with more severe depression, anxiety, pain, and sleep following allogeneic hematopoietic cell transplantation. Poster presentation at the 2018 BMT Tandem Meetings, BBMT 2018.

56. Wright N, Flynn KE, Brazauskas R, Hari P, D’Souza A. Patient-reported distress if prevalent in systemic light chain amyloidosis but not determined by severity of disease. Poster presentation at XVIth International Symposium on Amyloidosis, Kumamoto, Japan, Amyloid 2018.

57. Kilari D, Hari P, Qayed M, Fraser R, Davila O, Kumar S, Mark T, Nieto Y, D’Souza A. Improved Outcomes with Tandem Autologous Hematopoietic Cell Transplantation (AutoHCT) Compared to Single AutoHCT for Relapsed/Refractory Germ Cell Tumors: A Center for International Blood and Marrow Transplant Research Study. Poster presentation at Annual Genitourinary ASCO Meeting, February 2018.

1. Complexities in the Diagnosis and Management of Amyloidosis. 07/10/2016 http://www.ascopost.com/issues/july-10-2016/complexities-in-the-diagnosis-and-management-of-amyloidosis/ Invited educational case-based study with expert opinion in the ASCO Post